Type 1 diabetes, formerly called juvenile diabetes or insulin-dependent diabetes, is usually first diagnosed in children, teenagers, or young adults. In this form of diabetes, the beta cells of the pancreas no longer make insulin because the body’s immune system has attacked and destroyed them. Treatment for type 1 diabetes includes taking insulin shots or using an insulin pump, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.
Can the SARS-CoV-2 vaccine reactivate previously suppressed antibody responses and pave the way for a unified coronavirus vaccine?
Research studying the autoimmune response, in which the immune system kills the insulin-producing pancreatic islet beta cells, is a common topic of type 1 diabetes research.
Researchers at Karolinska Institutet in Sweden show how a molecule that they have identified stimulates the formation of new insulin-producing cells in zebrafish and mammalian tissue, through a newly described mechanism for regulating protein synthesis.
A new study performed has offered better knowledge about how genetic factors tend to impact the immune response of the body in type 1 diabetes.
Researchers at the University of Miami Miller School of Medicine have created RNA molecules that bind to human pancreatic beta cells, which generate insulin and are destroyed in type 1 and type 2 diabetes patients.
New advancements in the transplantation of stem cell-derived insulin-producing beta cells to cure type 1 diabetes have created substantial curiosity.
Scientists have observed for the very first time that insulin-producing cells in the pancreas are attacked by T lymphocytes during the evolution of Type 1 Diabetes.
A*STAR’s GIS and ID Labs have discovered KCNJ15, a gene linked to the human immune system’s ability to combat TB and maybe other infectious diseases.
When the pro-inflammatory pair, a receptor called CCR2 and its ligand CCL-2, get together, it increases the risk of developing type 1 diabetes, scientists report.
Scientists have completed the largest and most diverse genetic study of type 1 diabetes ever undertaken, identifying new drug targets to treat a condition that affects 1.3 million American adults.
Skeletal muscle makes up 30% to 40% of body weight and serves multiple functions like heat production and energy metabolism.
Researchers revealed a predicted causative role for certain cell types in type 1 diabetes by examining its genetic foundations.
For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small minority of patients, perhaps 15 percent across different types of cancer. Moreover, doctors cannot accurately predict which of their patients will respond.
According to a research team, headed by Decio L. Eizirik, MD, PhD, a Scientific Director from the Indiana Biosciences Research Institute Diabetes Center, new treatments for autoimmune disorders can be identified by studying both target tissues and the immune system together.
A potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease, has been demonstrated in a mouse model and using immune-reactive T cells from patients with Crohn's disease.
Scientists from the University of Utah School of Medicine have discovered a novel therapeutic target to treat type 1 diabetic patients.
In a quest to find the genetic factors that are fundamental to diabetic retinopathy, scientists from the University of Illinois Chicago (UIC) have also discovered a new method that can be employed as a template to investigate other types of diseases.
According to a new study, a novel T cell genetically engineered by scientists from The University of Arizona Health Sciences can target and attack pathogenic T cells that are responsible for causing Type 1 diabetes. These latest findings may result in new immunotherapy therapies.
Boston College Assistant Professor of Biology Emrah Altindis has received a three-year, $300,000-grant from the G. Harold and Leila Y. Mathers Foundation for research into childhood celiac disease.
Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.